SABSW · As filed with the SEC
SAB Biotherapeutics income statement, by fiscal year
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Income (Loss) · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | 0 | 1,322,410 | 2,238,991 | 23,904,181 | 60,876,078 |
| Grant | — | — | — | 23,904,181 | 60,876,078 |
| Research and development | 34,352,332 | 30,251,667 | 16,515,005 | 36,438,513 | 57,183,589 |
| General and administrative | 14,601,031 | 13,981,263 | 23,799,306 | 16,383,285 | 17,085,692 |
| Total operating expenses | 48,953,363 | 44,232,930 | 40,314,311 | 52,821,798 | 74,269,281 |
| Loss from operations | (48,953,363) | (42,910,520) | (38,075,320) | (28,917,617) | (13,393,203) |
| Changes in fair value of warrant liabilities | 62,754,186 | 5,385,009 | (4,823,237) | 10,399,200 | (4,151,068) |
| Gain on debt extinguishment of Paycheck Protection Program SBA Loan | — | — | — | 0 | 665,596 |
| Other income | — | — | — | 33,754 | 5,488 |
| Interest expense | — | — | (315,284) | (301,584) | (294,459) |
| Interest expense | (240,664) | (318,401) | — | — | — |
| Interest income | 1,432,032 | 1,285,998 | 584,966 | 71,072 | 23,115 |
| Other income | 3,133,784 | 2,452,605 | 435,089 | — | — |
| Warrant issuance expense | (4,852,292) | — | — | — | — |
| Total other income | 62,227,046 | 8,805,211 | (4,118,466) | 10,202,442 | (3,751,328) |
| Loss before income taxes | — | — | (42,193,786) | (18,715,175) | (17,144,531) |
| Income tax expense (benefit) | — | — | 0 | 25,629 | 0 |
| Net income (loss) | 13,273,683 | (34,105,309) | (42,193,786) | (18,740,804) | (17,144,531) |
| Other comprehensive income (loss): | |||||
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | 185,464 | 647 | — | — | — |
| Foreign currency translation gain (loss) | 136,456 | (162,477) | 26,420 | — | — |
| Total comprehensive income (loss) | 13,595,603 | (34,267,139) | (42,167,366) | — | — |
| Income (loss) per common share attributable to the Company's shareholders | |||||
| Basic income (loss) per common share | 0.22 | (3.68) | (7.64) | (0.43) | (0.63) |
| Diluted loss per common share | (0.79) | (3.68) | (7.64) | — | — |
| Weighted-average common shares outstanding - basic | 19,311,798 | 9,261,918 | 5,521,487 | 43,524,971 | 27,339,180 |
| Weighted-average common shares outstanding - diluted | 61,340,193 | 9,261,918 | 5,521,487 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.